Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1

Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

The druggable genome

Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305

Discovering High-Affinity Ligands for Proteins: SAR by NMR

Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,045

Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 2,002

Anatomy of hot spots in protein interfaces

Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988

A Hot Spot of Binding Energy in a Hormone-Receptor Interface

Clackson, T., & Wells, J. A. (1995) · Science · doi:10.1126/science.7529940 · Cited by 1,987

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785

Fpocket: An open source platform for ligand pocket detection

Guilloux, V. L., Schmidtke, P., & Tufféry, P. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-168 · Cited by 1,724

X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death

Muchmore, S. W., Sattler, M., Liang, H., Meadows, R. P., Harlan, J. E., Yoon, H. S., Nettesheim, D. G., Chang, B. S., Thompson, C. B., Wong, S., et al. (1996) · Nature · doi:10.1038/381335a0 · Cited by 1,467

A ‘Rule of Three’ for fragment-based lead discovery?

Congreve, M., Carr, R. A. E., Murray, C. W., & Jhoti, H. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02831-9 · Cited by 1,415

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,409

Coupling of folding and binding for unstructured proteins

Dyson, H. J., & Wright, P. E. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00289-0 · Cited by 1,327

Rational design of inhibitors that bind to inactive kinase conformations

Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,096

Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites

Laurie, A. T. R., & Jackson, R. M. (2005) · Computer applications in the biosciences · doi:10.1093/bioinformatics/bti315 · Cited by 1,049

A decade of fragment-based drug design: strategic advances and lessons learned

Hajduk, P., & Greer, J. (2007) · Nature reviews. Drug discovery · doi:10.1038/nrd2220 · Cited by 1,004

An empirical framework for binary interactome mapping

Venkatesan, K., Rual, J.-F. M., Vázquez, A., Stelzl, U., Lemmens, I. H., Hirozane-Kishikawa, T., Hao, T., Zenkner, M., Xin, X., Goh, K. I., et al. (2008) · Nature Methods · doi:10.1038/nmeth.1280 · Cited by 925

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

Nagar, B., Bornmann, W. G., Pellicena, P., Schindler, T. H., Veach, D. R., Miller, W. T., Clarkson, B. D., & Kuriyan, J. (2002) · PubMed · Cited by 923

Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery

Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 904

A simple physical model for binding energy hot spots in protein–protein complexes

Kortemme, T., & Baker, D. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202485799 · Cited by 819

Direct inhibition of the NOTCH transcription factor complex

Moellering, R. E., Cornejo, M., Davis, T. N., Bianco, C. D., Aster, J. C., Blacklow, S. C., Kung, A. L., Gilliland, D. G., Verdine, G. L., & Bradner, J. E. (2009) · Nature · doi:10.1038/nature08543 · Cited by 752

LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins

Hendlich, M., Rippmann, F., & Barnickel, G. (1997) · Journal of Molecular Graphics and Modelling · doi:10.1016/s1093-3263(98)00002-3 · Cited by 732

Insights into DNA recombination from the structure of a RAD51–BRCA2 complex

Pellegrini, L., Yu, D. S., Lo, T., Anand, S., Lee, M., Blundell, T. L., & Venkitaraman, A. R. (2002) · Nature · doi:10.1038/nature01230 · Cited by 704

The influence of lead discovery strategies on the properties of drug candidates

Keserű, G. M., & Makara, G. M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2796 · Cited by 647

Recent Developments in Fragment-Based Drug Discovery

Congreve, M., Chessari, G., Tisi, D., & Woodhead, A. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8000373 · Cited by 620

Structural Characterisation and Functional Significance of Transient Protein–Protein Interactions

Nooren, I., & Thornton, J. M. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01281-0 · Cited by 587

High-throughput crystallography for lead discovery in drug design

Blundell, T. L., Jhoti, H., & Abell, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd706 · Cited by 538

Druggability Indices for Protein Targets Derived from NMR-Based Screening Data

Hajduk, P. J., Huth, J. R., & Fesik, S. W. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049131r · Cited by 526

Site-directed ligand discovery

Erlanson, D. A., Braisted, A. C., Raphael, D. R., Randal, M., Stroud, R. M., Gordon, E. M., & Wells, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9367 · Cited by 466

The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer

Stewart, M. L., Fire, E., Keating, A. E., & Walensky, L. D. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.391 · Cited by 418

Towards third generation matrix metalloproteinase inhibitors for cancer therapy

Overall, C. M., & Kleifeld, O. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603043 · Cited by 351

Conformation of glucagon in a lipid-water interphase by 1H nuclear magnetic resonance

Braun, W. A., Wider, G., Lee, K. H., & Kurt Wüthrich, A. (1983) · Journal of Molecular Biology · doi:10.1016/s0022-2836(83)80143-0 · Cited by 340

Understanding and Predicting Druggability. A High-Throughput Method for Detection of Drug Binding Sites

Schmidtke, P., & Barril, X. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100574m · Cited by 337

Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL

Bruncko, M., Oost, T. K., Belli, B., Ding, H., Joseph, M. K., Kunzer, A. R., Martineau, D., McClellan, W. J., Mitten, M. J., Ng, S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061152t · Cited by 306

Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x L from NMR and Parallel Synthesis

Petros, A. M., Dinges, J., Augeri, D. J., Baumeister, S. A., Betebenner, D. A., Bures, M. G., Elmore, S. W., Hajduk, P. J., Joseph, M. K., Landis, S. K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0507532 · Cited by 303

A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53

Bernal, F., Wade, M. R., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 288

Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery

Pérot, S., Spérandio, O., Miteva, M. A., Camproux, A., & Villoutreix, B. O. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.05.015 · Cited by 287

X-ray analysis of glucagon and its relationship to receptor binding

Sasaki, K., Dockerill, S., Adamiak, D. A., Tickle, I. J., & Blundell, T. L. (1975) · Nature · doi:10.1038/257751a0 · Cited by 286

Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family

Lee, E. F., Czabotar, P. E., Smith, B. J., Deshayes, K., Zobel, K., Colman, P. M., & Fairlie, W. D. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402178 · Cited by 280

Inhibition of protein–protein interactions using designed molecules

Wilson, A. J. (2009) · Chemical Society Reviews · doi:10.1039/b807197g · Cited by 262

Discovery of a Potent Small Molecule IL-2 Inhibitor through Fragment Assembly

Braisted, A. C., Oslob, J. D., DeLano, W. L., Hyde, J., McDowell, R. S., Waal, N. D., Yu, C. H., Arkin, M. R., & Raimundo, B. C. (2003) · Journal of the American Chemical Society · doi:10.1021/ja034247i · Cited by 256

Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives

Zimmermann, J., Buchdunger, E., Mett, H., Meyer, T., & Lydon, N. (1997) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(96)00601-4 · Cited by 250

Structural Basis for the Highly Selective Inhibition of MMP-13

Engel, C. K., Pirard, B., Schimanski-Breves, S., Kirsch, R., Habermann, J., Klingler, O., Schlotte, V., Weithmann, K. U., & Wendt, K. U. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.11.014 · Cited by 229

A method for localizing ligand binding pockets in protein structures

Glaser, F., Morris, R. J., Najmanovich, R., Laskowski, R. A., & Thornton, J. M. (2005) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20769 · Cited by 219

Recent advances in MMP inhibitor design

Fisher, J. F., & Mobashery, S. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-7894-9 · Cited by 215

Shape Variation in Protein Binding Pockets and their Ligands

Kahraman, A., Morris, R. J., Laskowski, R. A., & Thornton, J. M. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.01.086 · Cited by 213

Discovery and Characterization of a Novel Inhibitor of Matrix Metalloprotease-13 That Reduces Cartilage Damage in Vivo without Joint Fibroplasia Side Effects

Johnson, A. R., Pavlovsky, A. G., Ortwine, D. F., Prior, F., Man, C.-F., Bornemeier, D. A., Banotai, C. A., Mueller, W. T., McConnell, P., Yan, C., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703286200 · Cited by 212

Fragment screening to predict druggability (ligandability) and lead discovery success

Edfeldt, F., Folmer, R. H. A., & Breeze, A. L. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.02.002 · Cited by 211

Structural biology in fragment-based drug design

Murray, C. W., & Blundell, T. L. (2010) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2010.04.003 · Cited by 206

The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis

Parish, T., & Stoker, N. G. (2002) · Microbiology · doi:10.1099/00221287-148-10-3069 · Cited by 198

Geometry of nonbonded interactions involving planar groups in proteins

Chakrabarti, P., & Bhattacharyya, R. (2007) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2007.03.016 · Cited by 197

Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery

Blundell, T. L., Sibanda, B. L., Montalvão, R. W., Brewerton, S. C., Chelliah, V., Worth, C. L., Harmer, N. J., Davies, O. R., & Burke, D. F. (2006) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2005.1800 · Cited by 186

Broad‐spectrum matrix metalloproteinase inhibitor marimastat–induced musculoskeletal side effects in rats

Renkiewicz, R. R., Qiu, L., Lesch, C. A., Sun, X., Devalaraja, R., Cody, T. T., Kaldjian, E. P., Welgus, H. G., & Baragi, V. M. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11030 · Cited by 171

A survey of available tools and web servers for analysis of protein-protein interactions and interfaces

Tunçbağ, N., Kar, G., Keskin, Ö., Gürsoy, A., & Nussinov, R. (2008) · Briefings in Bioinformatics · doi:10.1093/bib/bbp001 · Cited by 167

Atomic Interactions and Profile of Small Molecules Disrupting Protein–Protein Interfaces: the TIMBAL Database

Higueruelo, A. P., Schreyer, A. M., Bickerton, G. R., Pitt, W. R., Groom, C. R., & Blundell, T. L. (2009) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00889.x · Cited by 166

Hot-spot mimicry of a cytokine receptor by a small molecule

Thanos, C. D., DeLano, W. L., & Wells, J. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607058103 · Cited by 144

3did: identification and classification of domain-based interactions of known three-dimensional structure

Stein, A., Ceol, A. G. M., & Aloy, P. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq962 · Cited by 142

Probing Hot Spots at Protein−Ligand Binding Sites: A Fragment-Based Approach Using Biophysical Methods

Ciulli, A., Williams, G., Smith, A. G., Blundell, T. L., & Abell, C. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060490r · Cited by 137

Protein surface recognition and proteomimetics: mimics of protein surface structure and function

Fletcher, S., & Hamilton, A. D. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.10.006 · Cited by 129

Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database

Bourgeas, R., Basse, M.-J., Morelli, X., & Roche, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009598 · Cited by 126

The two types of 3-dehydroquinase have distinct structures but catalyze the same overall reaction

Coggins, J. R., Sawyer, L., Gourley, D. G., Shrive, A. K., Polikarpov, I., Krell, T., Hawkins, A. R., & Isaacs, N. W. (1999) · Nature Structural Biology · doi:10.1038/9287 · Cited by 119

Huntingtin in health and disease

Young, A. B. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17742 · Cited by 118

Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design

Chen, J., Nelson, F. C., Levin, J. I., Mobilio, D., Moy, F. J., Nilakantan, R., Zask, A., & Powers, R. (2000) · Journal of the American Chemical Society · doi:10.1021/ja001547g · Cited by 108

PocketDepth: A new depth based algorithm for identification of ligand binding sites in proteins

Yeturu, K., & Chandra, N. R. (2007) · Journal of Structural Biology · doi:10.1016/j.jsb.2007.09.005 · Cited by 106

Protein–protein interactions: organization, cooperativity and mapping in a bottom-up Systems Biology approach

Keskin, Ö., Ma, B., Rogale, K., Gunasekaran, K., & Nussinov, R. (2005) · Physical Biology · doi:10.1088/1478-3975/2/2/s03 · Cited by 101

Predictions of Hot Spot Residues at Protein-Protein Interfaces Using Support Vector Machines

Lise, S., Buchan, D. W. A., Pontil, M., & Jones, D. T. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016774 · Cited by 94

Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1′ cavity

Devel, L., Czarny, B., Beau, F., Georgiadis, D., Stura, E. A., & Dive, V. (2010) · Biochimie · doi:10.1016/j.biochi.2010.07.017 · Cited by 92

The Conformation, Flexibility, and Dynamics of Polypeptide Hormones

Blundell, T. L., & Wood, S. P. (1982) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.51.070182.001011 · Cited by 90

Large-Scale Comparison of Four Binding Site Detection Algorithms

Schmidtke, P., Souaille, C., Estienne, F., Baurin, N., & Kroemer, R. T. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci1000289 · Cited by 87

Extra Binding Region Induced by Non-Zinc Chelating Inhibitors into the S 1 ′ Subsite of Matrix Metalloproteinase 8 (MMP-8)

Pochetti, G., Montanari, R., Gege, C., Chevrier, C., Taveras, A. G., & Mazza, F. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801166j · Cited by 82

Rule of Three

Lin, J. C. (1985) · Cataloging & Classification Quarterly · doi:10.1300/j104v05n04_05 · Cited by 81

Bcl-XL Mutations Suppress Cellular Sensitivity to Antimycin A

Manion, M. K., O’Neill, J., Giedt, C. D., Kim, K. M., Zhang, K. Y. J., & Hockenbery, D. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306021200 · Cited by 81

Targeting the Shikimate Pathway in the Malaria Parasite Plasmodium falciparum

McConkey, G. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.175 · Cited by 78

Biochemical and X‐ray crystallographic studies on shikimate kinase: The important structural role of the P‐loop lysine

Krell, T., Maclean, J. K. F., Boam, D. J., Cooper, A., Resmini, M., Brocklehurst, K., Kelly, S. M., Price, N. C., Lapthorn, A. J., & Coggins, J. R. (2001) · Protein Science · doi:10.1110/ps.52501 · Cited by 76

Metalloform-Selective Inhibitors of Escherichia c oli Methionine Aminopeptidase and X-ray Structure of a Mn(II)-Form Enzyme Complexed with an Inhibitor

Ye, Q.-Z., Xie, S.-X., Huang, M., Huang, W.-J., Lu, J.-P., & Ma, Z.-Q. (2004) · Journal of the American Chemical Society · doi:10.1021/ja045864p · Cited by 73

Mechanism of Phosphoryl Transfer Catalyzed by Shikimate Kinase from Mycobacterium tuberculosis

Hartmann, M. D., Bourenkov, G. P., Oberschall, A., Strizhov, N., & Bartunik, H. D. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.09.001 · Cited by 72

Emerging trends in metalloprotein inhibition

Rouffet, M., & Cohen, S. M. (2011) · Dalton Transactions · doi:10.1039/c0dt01743d · Cited by 70

Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database

Bickerton, G. R., Higueruelo, A. P., & Blundell, T. L. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-313 · Cited by 66

Treatment of systemic lupus erythematosus with epratuzumab

Traczewski, P., & Rudnicka, L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03767.x · Cited by 61

Different mechanistic and stereochemical courses for the reactions catalysed by type I and type II dehydroquinases

Harris, J., Kleanthous, C., Coggins, J. R., Hawkins, A. R., & Abell, C. (1993) · Journal of the Chemical Society Chemical Communications · doi:10.1039/c39930001080 · Cited by 59

Effects of the magnesium and chloride ions and shikimate on the structure of shikimate kinase fromMycobacterium tuberculosis

Dias, M. V. B., Faim, L. M., Vasconcelos, I. B., de Oliveira, J. S., Basso, L. A., Santos, D. S., & de Azevedo, W. F. (2006) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309106046823 · Cited by 47

The use of electrospray mass spectrometry to identify an essential arginine residue in type II dehydroquinases

Krell, T., Pitt, A. R., & Coggins, J. R. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00083-l · Cited by 44

Structural investigation of inhibitor designs targeting 3-dehydroquinate dehydratase from the shikimate pathway of Mycobacterium tuberculosis

Dias, M. V. B., Snee, W. C., Bromfield, K. M., Payne, R. J., Palaninathan, S. K., Ciulli, A., Howard, N., Abell, C., Sacchettini, J. C., & Blundell, T. L. (2011) · Biochemical Journal · doi:10.1042/bj20110002 · Cited by 42

Novel therapeutics for Alzheimer's disease: an update.

Bonda, D., Lee, H. P., Lee, H., Friedlich, A. L., Perry, G. L., Zhu, X., & Smith, M. A. (2010) · PubMed · Cited by 41

Highly accurate method for ligand‐binding site prediction in unbound state (apo) protein structures

Morita, M., Nakamura, S., & Shimizu, K. (2008) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22067 · Cited by 39

Predicting protein-protein binding sites in membrane proteins

Bordner, A. J. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-312 · Cited by 37

Progress in type II dehydroquinase inhibitors: From concept to practice

González‐Bello, C., & Castedo, L. (2006) · Medicinal Research Reviews · doi:10.1002/med.20076 · Cited by 35

Crystallographic studies of shikimate binding and induced conformational changes in Mycobacterium tuberculosis shikimate kinase

Dhaliwal, B., Nichols, C. E., Ren, J., Lockyer, M. J., Charles, I. G., Hawkins, A. R., & STAMMERS, D. K. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.08.005 · Cited by 34

A Prodrug Approach for Improving Antituberculosis Activity of Potent Mycobacterium tuberculosis Type II Dehydroquinase Inhibitors

Tizon, L., Otero, J. M., Prazeres, V. F. V., Llamas-Saiz, A. L., Fox, G. C., van Raaij, M. J., Lamb, H. K., Hawkins, A. R., Aínsa, J. A., Castedo, L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006063 · Cited by 34

Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling

Buerger, C., & Groner, B. (2003) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0489-8 · Cited by 32

Structural Basis for Shikimate-Binding Specificity ofHelicobacter pyloriShikimate Kinase

Cheng, W., Chang, Y., & Wang, W. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.23.8156-8163.2005 · Cited by 30

Conformation and molecular biology of polypeptide hormones II. Glucagon

Blundell, T. L. (1979) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(79)90187-7 · Cited by 13

Third-Generation MMP Inhibitors: Recent Advances in the Development of Highly Selective Inhibitors

Yiotakis, A., & Dive, V. (2008) · Springer eBooks · doi:10.1007/978-0-387-69057-5_38 · Cited by 11

DAPID: a 3D-domain annotated protein-protein interaction database.

Chen, Y.-C., Chen, H. C., & Yang, J. (2006) · PubMed · Cited by 10

Hormone-receptor interactions: a study of the binding of hormone-substituted tobacco mosaic virus to membrane vesicles by dynamic light scattering and by transient electric bi-refringence

Schwyzer, R., Kriwaczek, V. M., Baumann, K., Haller, H. R., Wider, G., & Wiltzius, P. (1979) · Pure and Applied Chemistry · doi:10.1351/pac197951040831 · Cited by 8

Molecular characterization and evolutionary plasticity of protein-protein interfaces

Bickerton, G. R. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique) · doi:10.17863/cam.16525 · Cited by 3

Role of Molecular Dynamics and Related Methods in Drug Discovery

Vivo, M. D., Masetti, M., Bottegoni, G., & Cavalli, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01684 · Cited by 1,358

Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates

Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835

Inhibition of α-helix-mediated protein–protein interactions using designed molecules

Azzarito, V., Long, K., Murphy, N. S., & Wilson, A. J. (2013) · Nature Chemistry · doi:10.1038/nchem.1568 · Cited by 727

Discovery of small molecule cancer drugs: Successes, challenges and opportunities

Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 591

Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?

Giordanetto, F., & Kihlberg, J. O. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400887j · Cited by 577

Structural conservation of druggable hot spots in protein–protein interfaces

Kozakov, D., Hall, D. R., Chuang, G., Cencic, R., Brenke, R., Grove, L. E., Beglov, D., Pelletier, J., Whitty, A., & Vajda, S. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1101835108 · Cited by 245

Finding Small Molecule Ligands for Protein-Protein Interactions and Other “Undruggable” Targets

Arkin, M. R. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2009.12.2216

Protein Flexibility: A Challenging Issue of Drug Discovery

Gupta, S. P. (2018) · Current Chemical Biology · doi:10.2174/2212796812666180524100212 · Cited by 3

Emerging Target Families: Intractable Targets

Knapp, S. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_28 · Cited by 9

How Different are Structurally Flexible and Rigid Binding Sites? Sequence and Structural Features Discriminating Proteins that Do and Do not Undergo Conformational Change upon Ligand Binding

Gunasekaran, K., & Nussinov, R. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.09.062 · Cited by 144